Route-dependent systemic and local immune effects following exposure to solutions prepared from titanium dioxide nanoparticles

Journal of Immunotoxicology

Volumn 11, Issue 3, 2014, Pages 273-282

  Auttachoat, Wimolnut ^a,c   McLoughlin, Colleen E ^a,b   White Jr , Kimber L ^a   Smith, Matthew J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Virginia Commonwealth University   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

Contact hypersensitivity; Immune response; Immunotoxicity; Nanoparticles; Titanium dioxide

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN M ANTIBODY; TITANIUM DIOXIDE NANOPARTICLE; COSMETIC; IMMUNOGLOBULIN M; NANOPARTICLE; PAINT; TITANIUM; TITANIUM DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANDIDA ALBICANS; CELL PROLIFERATION; CELL SUSPENSION; COMPARATIVE STUDY; CONTACT ALLERGY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENVIRONMENTAL EXPOSURE; FEMALE; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTOXICITY; INNATE IMMUNITY; KIDNEY MASS; LIVER WEIGHT; LUNG WEIGHT; LYMPH NODE CELL; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SHEEP ERYTHROCYTE; SPLEEN WEIGHT; THYMUS WEIGHT; WEIGHT CHANGE; ANIMAL; BLOOD; C3H MOUSE; C57BL MOUSE; CHEMISTRY; CONTACT DERMATITIS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; LYMPHOCYTE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; COSMETICS; DERMATITIS, CONTACT; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN M; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NANOPARTICLES; PAINT; SKIN; TITANIUM;

EID: 84896471949     PISSN: 1547691X     EISSN: 15476901     Source Type: Journal    
DOI: 10.3109/1547691X.2013.844750     Document Type: Article

References (67)

1. Anderson, P. K., Woolhiser, M. R., Rase, J. M., and Holsapple, M. P. 2003. Integration of primary irritation with the LLNA. The Toxicologist 72:492.
2. Anderson, S. E., Siegel, P. D., and Meade, B. J. 2011. The LLNA: A brief review of recent advances and limitations. J. Allergy 2011:424203.
3. Arys, A., Philippart, C., Dourov, N., et al. 1998. Analysis of titanium dental implants after failure of osseointegration: Combined histo-logical, electron micro-scopy, and X-ray photoelectron spectroscopy approach. J. Biomed. Mater. Res. 43:300-312.
4. Ashby, J., and Tennant, R. W. 1991. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 257:229-306.
5. Auttachoat, W., Chitsomboon, B., Peachee, V. L., et al. 2004. Immunomodulation by Don Din Daeng (Aeginetia indica Roxb.) extracts in female B6C3F1 mice: II. Humoral immunity, innate immunity and hematology. Int. Immunopharmacol. 4:1381-1390.
6. Baan, R., Straif, K., Grosse, Y., et al. 2006. Carcinogenicity of carbon black, titanium dioxide, and talc. Lancet Oncol. 7:295-296.
7. Borm, P. J., Robbins, D., Haubold, S., et al. 2006. The potential risks of nanomaterials: A review carried out for ECETOC. Part. Fibre Toxicol. 3:11.
8. Brien, W.W., Salvati, E. A., Betts, F., et al. 1992. Metal levels in cemented total hip arthroplasty. A comparison of well-fixed and loose implants. Clin. Orthoped. Related Res. 264:66-74.
9. Buly, R. L., Huo, M. H., Salvati, E., et al. 1992. Titanium wear debris in failed cemented total hip arthroplasty. An analysis of 71 cases. J. Arthroplasty 7:315-323.
10. CEC (Commission of the European Communities). 1995. Commission directive 95/45/EC of 26 July 1995 laying down specific purity criteria concerning colors for use in foodstuffs. Available online at: http://ec.europa.eu/food/fs/sfp/ addit-flavor/flav13-en.pd [last accessed 29 July 2013].
11. Cedarvall, T., Lynch, I., Lindman, S., et al. 2007. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. USA 104:2050-2055.
12. Cho, W. S., Kang, B. C., Lee, J. K., et al. 2013. Comparative absorption, distribution, and excretion of titanium dioxide and zinc oxide nanoparticles after repeated oral administration. Part. Fibre Toxicol. 10:9.
13. Cunningham, B. W., Orbegoso, C. M., Dmitriev, A. E., et al. 2002. The effect of titanium particulate on development and maintenance of a postero-lateral spinal arthrodesis: An in vivo rabbit model. Spine 27: 1971-1981.
14. Dobrovolskaia, M. A., Germolec, D. R., and Weaver, J. L. 2009. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4: 411-414.
15. Dooley, A., Gao, B., Bradley, N., et al. 2006. Abnormal nitric oxide metabolism in systemic sclerosis: Increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 45: 676-684.
16. Duan, Y., Liu, J., Ma, L., et al. 2010. Toxicological characteristics of nanoparticulate anatase titanium dioxide in mice. Biomaterials 31: 894-899.
17. EFSA (European Food Safety Authority). 2004. Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food on a request from the Commission related to the safety in use of rutile titanium dioxide as an alternative to the presently permitted anatase form. Available online at: http://efsa.europa.eu/en/efsajournal/doc/163.pdf [last accessed 9 September 2013].
18. Furukawa, F., Doi, Y., Suguro, M., et al. 2010. Lack of skin carcinogen-icity of topically applied titanium dioxide nanoparticles in the mouse. Food Chem. Toxicol. 49:744-749.
19. Gad, S. C., Dunn, B. J., Dobbs, D. W., et al. 1986. Development and validation of an alternative dermal sensitization test: The mouse ear-swelling test (MEST). Toxicol. Appl. Pharmacol. 84:93-114.
20. Gamer, A. O., Leibold, E., and van Ravenzwaay, B. 2006. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol. In Vitro 20:301-307.
21. Gerhardt, L. C., Jell, G. M., and Boccaccini, A. R. 2007. Titanium dioxide (TiO2) nanoparticles filled poly(D, L-lactid acid) (PDLLA) matrix composites for bone tissue engineering. J. Mater. Sci. Mater. Med. 18: 1287-1298.
22. Greenacre, S. A., Rocha, F. A., Rawlingson, A., et al. 2002. Protein nitration in cutaneous inflammation in the rat: Essential role of inducible nitric oxide synthase and polymorphonuclear leukocytes. Br. J. Pharmacol. 136:985-994.
23. Hussain, S., Smulders, S., de Vooght, V., et al. 2012. Nano-titanium dioxide modulates the dermal sensitization potency of DNCB. Part. Fibre Toxicol. 9:15.
24. IARC (International Agency for Research on Cancer). 2006. Monographs on the evaluation of carcinogenic risks to humans. Carbon Black, Titanium Dioxide and Non-Asbestiform Talc. Vol 93. Geneva: World Health Organization.
25. Jani, P. U., McCarthy, D. E., and Florence, A. T. 1994. Titanium Dioxide (rutile) particle uptake from the rat GI tract and translocation to systemic organs after oral administration. Int. J. Pharmaceut. 105: 157-168.
26. Jerne, N. K., and Nordin, A. A. 1963. Plaque formation in agar by single antibody-producing cells. Science 140:405-406.
27. Kawabata, T. T., Babcock, L. S., Gauggel, D. L., et al. 1995. Optimization and validation of an ELISA to measure specific guinea pig IgG 1 antibody as an alternative to the in vivo passive cutaneous anaphylaxis assay. Fundam. Appl. Toxicol. 24:238-246.
28. Lademann, J., Weigmann, H., Rickmeyer, C, et al. 1999. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol. Appl. Skin Physiol. 12:247-256.
29. Li, N, Duan, Y., Hong, M., et al. 2010. Spleen injury and apoptotic pathway in mice caused by titanium dioxide nanoparticules. Toxicol. Lett. 195:161-168.
30. Liao, C. M., Chiang, Y H., and Chio, C. P. 2008. Model-based assessment for human inhalation exposure risk to airborne nano/fine titanium dioxide particles. Sci. Total Environ. 407:165-177.
31. Lu, N, Zhu, Z., Zhao, X., et al. 2008. Nano titanium dioxide photo-catalytic protein tyrosine nitration: A potential hazard of TiO2 on skin. Biochem. Biophys. Res. Commun. 370:675-680.
32. Ma-Hock, L., Strauss, V., Treumann, S., et al. 2013. Comparative inhalation toxicity of multi-wall carbon nanotubes, graphene, graphite nanoparticles, and low surface carbon black. Part. Fibre Toxicol. 10:23.
33. Mavon, A., Miquel, C, Lejeune, O., et al. 2007. In vitro percutaneous absorption and in vivo stratum corneum distribution of an organic and a mineral sunscreen. Skin Pharmacol. Physiol. 20:10-20.
34. Miyauchi, T., Yamada, M., Yamamoto, A., et al. 2010. The enhanced characteristics of osteoblast adhesion to photofunctionalized nanoscale TiO 2 layers on biomaterials surfaces. Biomaterials 31:3827-3839.
35. Monopoli, M. P., Aberg, C, Salvati, A., and Dawson, K. A. 2012. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7:779-786.
36. Mueller, N. C, and Nowack, B. 2008. Exposure modeling of engineered nanoparticles in the environment. Environ. Sci. Technol. 42: 4447-453.
37. Müller, K., and Valentine-Thon, E. 2006. Hypersensitivity to titanium: Clinical and laboratory evidence. NeuroEndocrinol Lett. 27:31-35.
38. National Cancer Institute, Carcinogenesis, Technical Report Series No.97. 1979. Bioassay of titanium dioxide for possible carcinogenicity (CAS No. 3463-67-7) NCI-CG-TR-97. Available online at: http://ntp.niehs.gov/ntp/htdocs/ LT-rpts/tr097.pdf [last accessed 10 Sep 2013].
39. Newman, M. D., Stotland, M., and Ellis, J. I. 2009. The safety of nanosized particles in titanium dioxide-and zinc oxide-based sunscreens. J. Am. Acad. Dermatol. 61:685-692.
40. NIH. 1999. The murine local lymph node assay: A test method for assessing the allergic contact dermatitis potential of chemicals/compounds. NIH Publication No. 99-4494
41. NMI (National Measurement Institute). 2012. XRD Phase Analysis of TiO2 Sunscreens. Australian Government, NMI. Available from: http://libcloud.s3. amazonaws.com/93/5a/1/2746/NMI-report-XRD-anata-se.pdf [last accessed 29 July 2013].
42. Olmos, A., Giner, R. M., Recio, M. C, et al. 2007. Effects of plant alkylphenols on cytokine production, tyrosine nitration and inflammatory damage in the efferent phase of contact hypersensitivity. Br. J. Pharmacol. 152:366-373.
43. Pflucker, F., Wendel, V., Hohenberg, H, et al. 2001. The human stratum corneum layer: An effective barrier against dermal uptake of different forms of topically applied micronised titanium dioxide. Skin Pharmacol. Appl. Skin Physiol. 14:92-97.
44. Ratner, B. D. 2004. Biomaterials Science: An Introduction to Biomaterials in Medicine, Chapter 3, 2nd ed (Ratner, B. D., Hoffman, A. S., Schoen, F. J., and Lemons, J. E., Eds.). London: Elsevier Academic Press.
45. Sadrieh, N, Wokovich, A. M., Gopee, N.V., et al. 2010. Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano-and submicron-size TiO2 particles. Toxicol. Sci. 115:156-166.
46. SCCP (Scientific Committee on Consumer Products). 2007. SCCP/1147/07: Opinion on safety of nanomaterial in cosmetic products. Adopted by the SCCP after the public consultation on the 14th Plenary of 18 December 2007. Available online at: http://ec.europa.eu/health/ph-risk/committees/04-sccp/docs/sccp-o- 123.pdf [last accessed 10 Sep 2013].
47. Schulz, J., Hohenberg, H, Pflucker, F., et al. 2002. Distribution of sunscreens on skin. Adv. Drug Deliv. Rev. 54:S157-S163.
48. Shelby, M. D. 1988. The genetic toxicity of human carcinogens and its implications. Mutat. Res. 204:3-15.
49. Shelby, M. D., and Zeiger, E. 1990. Activity of human carcinogens in the Salmonella and rodent bone-marrow cytogenetics tests. Mutat. Res. 234:257-261.
50. Shin, J. A., Lee, E. J., Seo, S. M., et al. 2010. Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse. Neuroscience 165:445-54.
51. Sigma-Aldrich. 2009. Certificate of Analysis: Titanium(IV) oxide, anatase, nanopowder, <25nm particle size. St. Louis, MO: Sigma-Aldrich.
52. Smith, C. M., Roy, T D., Bhalkikar, A., et al. 2010a. Engineering a titanium and polycaprolactone construct for a biocompatible interface between the body and artificial limb. Tissue Eng. Part A 16:717-724.
53. Smith, D. C, Smith, M. J., and White Jr., K. L. 2010b. Systemic immunosuppression following a single pharyngeal aspiration of 1, 2:5, 6-dibenzanthracene in female B6C3F1 mice. J. Immunotoxicol. 7:219-231.
54. Smith, M. J., and White Jr., K. L. 2010. Establishment and comparison of delayed-type hypersensivity models in the B6C3F1 mouse. J. Immunotoxicol. 7:308-317.
55. Stokes, R., and Diffey, B. 1997. How well are sunscreen users protected? Photodermatol. Photoimmunol. Photomed. 13:186-188.
56. Szabo, E., Virag, L., Bakondi, E., et al. 2001. Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J. Invest. Dermatol. 117:74-80.
57. Temple, L., Kawabata, T T, Munson, A. E., and White Jr., K. L. 1993. Comparison of ELISA and plaque-forming cell assays for measuring the humoral immune response to SRBC in rats and mice treated with benzo[a]pyrene or cyclophosphamide. Fundam. Appl. Toxicol. 21: 412-419.
58. TGA. 2006. A review of the scientific literature on the safety of nanoparticulate titanium dioxide or zinc dioxide in sunscreens. Australian Government, OTC Medicines Section. Available online at: http://www.tga.gov.au/ npmeds/sunscreen-zotd.pdf [last accessed 10 Sep 2013].
59. U.S. Food and Drug Administration (FDA). 2010. CFR-Code of Federal Regulations Title 21, Volume 1-Food and Drugs, Chapter 1-Food and Drug Administration. Department of Health and Human Services. Subchapter A-general, part 73-listing of color additives exempt from certification. Revised on April 1, 2010. 21 CFR73.575. Available online at: http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.575 [last accessed 10 Sep 2013].
60. Walkey, C. D., Olsen, J. B., Guo, H, et al. 2012. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134:2139-2147.
61. Wang, J., Zhou, G, Chen, C, et al. 2007. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol. Lett. 168:176-185.
62. Weaver, J. L., Chapdelaine, J. M., Descotes, J., et al. 2005. Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions. J. Immunotoxicol. 2:11-20.
63. Weir, A., Westerhoff, P., Fabricius, L., et al. 2012. Titanium dioxide nanoparticles in food and personal care products. Environ. Sci. Technol. 46:2242-2250.
64. White, K. L., Musgrove, D. L., and Brown, R. D. 2010. The sheep erythrocyte T-dependent antibody response (TDAR). Methods Mol. Biol. 598:173-184.
65. Witt, K. L., Knapton, A., Wehr, C. M., et al. 2000. Micronucleated erythrocyte frequency in peripheral blood of B6C3F1 mice from short-term, prechronic, and chronic studies of the NTP carcinogenesis bioassay program. Environ. Mol. Mutagen. 36:163-194.
66. Woolhiser, M. R., Hayes, B. B., and Meade, B. J. 1998. A combined murine local lymph node and irritancy assay to predict sensitization and irritancy potential of chemicals. Toxicol. Mech. Meth. 8:245-256.
67. World Health Organization. 1969. FAO Nutrition Meeting Report Series No. 46 A: Toxicological evaluation of some food colors, emulsifers, stabilizers, anti-caking agents, and certain other substances. Geneva: WHO/FOOD ADD/70.36.